secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sarepta Therapeutics, Inc. (SRPT)
CIK:        0000873303
Form:       8-K
Filed at:   2022-12-13T23:59:59+00:00
Accession:  0001193125-22-303900
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sarepta amends bylaws for universal proxy rules and DGCL updates
----------------------------------------------------------------

- Board approved Second Amended and Restated Bylaws, effective December 9, 2022.
- Adds advance notice provisions to comply with SEC universal proxy Rule 14a-19.
- Stockholders must represent intent to solicit proxies under Rule 14a-19 and provide prompt notice of failures.
- Amendments reflect DGCL changes re: adjournment of meetings and elimination of stockholder list requirement.
- No successor or substitute nominees allowed after the nomination deadline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/873303/000119312522303900/0001193125-22-303900-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/873303/000119312522303900/d424180d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-303900

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer